Key result
Belatacept shows no difference in arterial stiffness or phase angle versus CNIs in renal transplant recipients.
Why the study?
There are few studies regarding differences in arterial stiffness and body composition between renal transplant recipients receiving belatacept versus calcineurin inhibitors.
Does belatacept-based immunosuppression improve arterial stiffness and phase angle compared to calcineurin inhibitor-based immunosuppression in renal transplant recipients?
Observational (n=325)
Does belatacept-based immunosuppression improve arterial stiffness and phase angle compared to calcineurin inhibitor-based immunosuppression in renal transplant recipients?
Immunosuppressive regimens based on belatacept versus calcineurin inhibitors do not significantly differ in their impact on arterial stiffness and phase angle in renal transplant recipients.
Answers are grounded in this paper and cite their sources.
No vascular benefit seen with belatacept versus CNIs; leaves open whether prospective trials would detect differences in arterial stiffness among renal transplant recipients.
BACKGROUND: Arterial stiffness and phase angle (PhA) have gained importance as a diagnostic and prognostic parameter in the management of cardiovascular disease. There are few studies regarding the differences in arterial stiffness and body composition between renal transplant recipients (RTRs) receiving belatacept (BELA) vs. calcineurin inhibitors (CNI). Therefore, we investigated the differences in arterial stiffness and body composition between RTRs treated with different immunosuppressants, including BELA. METHODS: In total, 325 RTRs were enrolled in the study (mean age 52.2 years, M -62.7%). Arterial stiffness was determined with an automated oscillometric device. All body composition parameters were assessed, based on bioelectrical impedance analysis (BIA), and laboratory parameters were obtained from the medical files of the patients. RESULTS: We did not detect any significant difference in terms of arterial stiffness and PhA in RTRs undergoing different immunosuppressive regimens, based on CsA, Tac, or BELA. Age was an essential risk factor for greater arterial stiffness. The PhA was associated with age, BMI, time of dialysis before transplantation, and kidney graft function. CONCLUSION: No significant differences in arterial stiffness and PhA were observed in RTRs under different immunosuppressive regimens. While our data provide additional evidence for arterial stiffness and PhA in RTRs, more research is needed to fully explore these cardiovascular risk factors and the impact of different immunosuppressive regimens.
No takes yet. Share an insight, caveat, or question.
Heleniak et al. (2022) conducted an observational in Renal transplant recipients (n=325). Belatacept-based immunosuppression vs. Calcineurin inhibitor-based immunosuppression (CsA or Tac) was evaluated on Arterial stiffness and phase angle (PhA). Belatacept-based immunosuppression showed no significant differences in arterial stiffness and phase angle compared to calcineurin inhibitors in 325 renal transplant recipients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: